NCT03737435Completed
Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study
Source: ClinicalTrials.gov · Last updated 22 Sept 2025
Brief summary (registry, in English)
International, multicenter retrospecitve biological study
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 8 Nov 2018
- Start date
- 12 Dec 2018
- Primary completion date
- 25 Oct 2024
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Diseases
- Childhood cancers
- NCT number
- NCT03737435
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From 12 Dec 2018 to the primary completion date, 25 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\) Patients with diagnosis different from osteosarcoma
- \-
Who the study is looking for
- Patients with primary localized osteosarcoma who received chemotherapy +/- mifamurtide according to ISG-OS2/GEIS-33 trials,
- Paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the biological analysis
- Written informed consent prior to any study-specific analysis and/or data collection
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SSD Chemioterapia dei tumori dell'apparato locomotore Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.